Max Kates

Associate Professor of Urology and Oncology
Director, Division of Urologic Oncology @bradyurology

[Max Kates @MaxKates]

Big congrats our BCAN Quale Fellows. And thank you to all the reviewers in this incredibly competitive application cycle We are fortunate to be in a golden age of bladder cancer progress. Thrilling to see that we are able to recruit such talent to the field.
@BladderCancerUS

[Bladder Cancer Advocacy Network @BladderCancerUS]

Congratulations to the 2026 John Quale Travel Fellowship recipients! We are proud to support the next generation of bladder cancer researchers and clinicians as they join us at the 2026 Bladder Cancer Think Tank. Your dedication to advancing bladder cancer research will help shape the future of patient care. @UofCalifornia @MSKCancerCenter @WeillCornell @Yale @theNCI @UW @MoffittNews @UHhospitals

[Max Kates @MaxKates]

Interesting thought experiment. If you take the 5% absolute difference in RFS, and instead give BCG +IO as reinduction after the 10% of all patients recur at 3mo, would you get same benefit of IO and limit toxicity/over treatment? @WesKassouf @UroDocAsh

[Wes Kassouf @WesKassouf]

Agree. The other question is does combo therapy for all outperforms sequential therapy for only some ( ie bcg for hr-nmibc then IO upon HG recurrence). I have not yet seen convincing data to suggest outcomes would be different between the two approaches

[Wes Kassouf @WesKassouf]

Agree. The other question is does combo therapy for all outperforms sequential therapy for only some ( ie bcg for hr-nmibc then IO upon HG recurrence). I have not yet seen convincing data to suggest outcomes would be different between the two approaches

[Max Kates @MaxKates]

6. Finally, we need to better understand why Alban was negative, CREST was marginally positive but company pulled FDa registration for now (unclear exactly why) & POTOMAC approved based on marginal improvements

7. Multiple trials in same space force us to interpret collectively

[Max Kates @MaxKates]

1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS)
2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok
3) little weight given to efficacy vs toxicity balance of a drug

[FDA Oncology @FDAOncology]

#FDA approves a treatment for high-risk non-muscle invasive bladder cancer. https://t.co/KHPP0Drkg0

[Max Kates @MaxKates]

4. Any NMIBC patient I am considering for early cystectomy i think reasonable to consider BCG +IO if patient wants bladder preservation

5. Trials didn't address who is highest risk, but we know multifocal HGT1 w/CIS is the bad actor so these folks who may benefit. Time will tell

[Vignesh Packiam, MD @VigneshPackiam]

If BRIDGE shows non-inferiority (I think likely)... need to choose treatments in real world. One of main issues if Gem/Doce is logistics, especially in community.

But there is also a time burden on the patient which can impact shared decision making

https://t.co/zyzToUgypq

[(GBCI) Greenberg Bladder Cancer Institute @HopkinsGBCI]

Marianna Zahurak • @MaxKates • Michael Goldstein • @nirmishsingla • Noah Hahn • @noel_onika • Roy Elias • @Imaging4Health • Stephanie Russell •
@SHPatelMD1 • Tamara Lotan

@brady_urology @hopkinskimmel

[(GBCI) Greenberg Bladder Cancer Institute @HopkinsGBCI]

Aditya Halthore • @Andres_Matoso • @akfsurgeon • Rusty Johnson • @cjvand • Daniel Song • Dorothy Davis • Dorothy Rosenthal • Ezra Baraban • @JCensits • @jonathandudley • Jun Luo • Kalli Veldman

[(GBCI) Greenberg Bladder Cancer Institute @HopkinsGBCI]

Collaboration in Action!
Our Working Groups bring together multidisciplinary experts committed to advancing bladder cancer research and care. Together, we’re tackling the most pressing challenges and turning ideas into impact.
Stay tuned to learn more about the people/progress

[The Johns Hopkins Brady Urological Institute @brady_urology]

View our schedule for the final day of #AUA26!

Thank you to everyone from @brady_urology who presented, attended, and contributed to the #AUA26 Annual Meeting!

You can find our full AUA schedule and more resources for clinicians here: https://t.co/RgYW0IkIUo

[Max Kates @MaxKates]

Superstar
@brady_urology
resident Tyler Garman presenting on the TIDE trial
@gr

[Joshua Meeks @JoshMeeks]

@eugene_pietzak incrediblely elegant P2 on bcg + Pembro in VHR T1. 92% response, 94% RC- free. 1 early death and 21% iAEs. n=37 but great job to consider risk - based strategy. #AUA26

[The Johns Hopkins Brady Urological Institute @brady_urology]

@brady_urology #AUA26 Saturday afternoon sessions

[The Johns Hopkins Brady Urological Institute @brady_urology]

We have a full day on Saturday for #AUA26! Preview our afternoon schedule.

View all of our sessions here: https://t.co/RgYW0IkIUo

[Max Kates @MaxKates]

Cc @HopkinsGBCI @brady

[UroToday.com @urotoday]

The #EMBRACETrial: An enhanced recovery after surgery pathway for transurethral resection of bladder tumors. @mihiggins22 & @MaxKates @brady_urology join @UroCancerMD to discuss an enhanced recovery protocol for ambulatory TURBT which improved Quality of Recovery-15 scores by 12 points—well above the 6-point clinical significance threshold—and reduced urethral pain, dysuria, incontinence, and 30-day outpatient visits. #WatchNow to learn more > https://t.co/I9sK9TBuwX

[UroToday.com @urotoday]

The #EMBRACETrial: An enhanced recovery after surgery pathway for transurethral resection of bladder tumors. @mihiggins22 & @MaxKates @brady_urology join @UroCancerMD to discuss an enhanced recovery protocol for ambulatory TURBT which improved Quality of Recovery-15 scores by 12 points—well above the 6-point clinical significance threshold—and reduced urethral pain, dysuria, incontinence, and 30-day outpatient visits. #WatchNow to learn more > https://t.co/I9sK9TBuwX

[(GBCI) Greenberg Bladder Cancer Institute @HopkinsGBCI]

An exciting step toward more personalized, precise care! Dr. Armine Smith (GBCI) is advancing AI-driven biomarkers for bladder cancer. This real-world study highlights how AI can support clinical decision making and is already gaining global attention. https://t.co/wVNMtjnwhS

[(GBCI) Greenberg Bladder Cancer Institute @HopkinsGBCI]

Reintroducing the GBCI.

Bringing together global, multidisciplinary experts to drive innovation in research, prevention, and treatment. Focused on bladder, upper tract urothelial cancer, and women’s bladder cancer.

Understand. Prevent. Cure.

[(GBCI) Greenberg Bladder Cancer Institute @HopkinsGBCI]

May is Bladder Cancer Awareness Month 🎗️Learn the facts about bladder cancer, including who’s at risk, how it's diagnosed, and the latest treatment options.
Bladder Cancer Q&A | Max Kates, M.D. https://t.co/kqDqVdXd87 via @YouTube